Go Back
Go Back

Day 2

49 Ch. Kontovounisios - Case: Pelvic recurrence after rectal cancer resection

49 Ch. Kontovounisios - Case: Pelvic recurrence after rectal...

50 E. Mosa - B. Re-irradiation in a previously irradiated pelvis - dose constraints, IMRT/proton options, sequencing.

50 E. Mosa - B. Re-irradiation in a previously irradiated pe...

51 B. Brenner - C. Induction chemo and IO before re-resection - converting borderline disease, re-staging timing.

51 B. Brenner - C. Induction chemo and IO before re-resectio...

52 P. Nikolopoulos - D. PET-CT and MRI in pelvic recurrence - resectability, R0 prediction, ruling out occult distant disease.

52 P. Nikolopoulos - D. PET-CT and MRI in pelvic recurrence...

53 Ch. Veros - Part 1: Genes / penetrance / surveillance.

53 Ch. Veros - Part 1: Genes / penetrance / surveillance.

54 M. Yurgelun - Part 3: Latest on prevention - aspirin, resistant starch, vaccines.

54 M. Yurgelun - Part 3: Latest on prevention - aspirin, res...

55 K. Stamou - Case: Peritoneal metastases from CRC: CRS-HIPEC or systemic therapy?

55 K. Stamou - Case: Peritoneal metastases from CRC: CRS-HIP...

56 E. Lavda - A. Imaging peritoneal metastases - what CT/MRI/PET can define, and what they cannot.

56 E. Lavda - A. Imaging peritoneal metastases - what CT/MRI...

57 B. Jansen-Winkeln - B. Diagnostic laparoscopy and PCI scoring before cytoreduction - practical workflow; when CT underestimates peritoneal burden and how laparoscopy changes the decision.

57 B. Jansen-Winkeln - B. Diagnostic laparoscopy and PCI sco...

58 G. Papaxoinis - C. First treatment decision - upfront CRS or induction systemic therapy: regimen choice in RAS WT/MSS disease, use of anti-EGFR therapy, response assessment & reassessment timing.

58 G. Papaxoinis - C. First treatment decision - upfront CRS...

59 K. Stamou - D. Local treatment strategy - CRS, HIPEC or CRS alone: completeness of cytoreduction, center expertise, morbidity, PRODIGE 7 implications, choice of HIPEC regimen where used.

59 K. Stamou - D. Local treatment strategy - CRS, HIPEC or C...

60 M. Drikou - Case: Synchronous rectal cancer & liver metastases: which comes first?

60 M. Drikou - Case: Synchronous rectal cancer & liver metas...

61 P. Lykoudis - A. Surgical sequencing - liver-first vs rectal-first vs simultaneous; what drives the choice.

61 P. Lykoudis - A. Surgical sequencing - liver-first vs rec...

62 M. Glynos - B. FLR volumetry, ablation + resection hybrid, hepatic arterial planning - what IR adds to the synchronous disease MDT decision.

62 M. Glynos - B. FLR volumetry, ablation + resection hybrid...

63 M. Avgoustidou - C. Conversion chemotherapy: how response defines resectability; RAS WT and left sidedness - which regimen maximizes response while preserving surgical options?

63 M. Avgoustidou - C. Conversion chemotherapy: how response...